Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

NCT ID: NCT06462768

Last Updated: 2024-06-17

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 260 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-11-27
• Study Completion Date: 2029-04-27

Brief Summary

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS).

Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called "NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE.

The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.

Detailed Description

This study is designed to assess the role of Neutrophil Extracellular Traps (NETs) in Systemic SClerosis (SSC) as well as to evaluate the correlation between NETs production and NETs composition and the different complications and phenotypes observed in SSC.

100 SSC patients, 30 other connective tissue disease patients and 130 healthy subjects will be recruited. Blood samples will be collected to obtain plasma, serum and polynuclear neutrophils by negative selection.

Conditions

Systemic Sclerosis; Other Connective Tissue Disease; Systemic Lupus Erythematosus; Dermatomyositis; ANCA Associated Vasculitis

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Adult with SSc

Adult with SSc

Blood sample

Intervention Type: OTHER

Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Other connective tissue disease

Adult with other connective tissue disease

Blood sample

Intervention Type: OTHER

Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Control

Healthy adult volunteer

Blood sample

Intervention Type: OTHER

Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Interventions

Blood sample

Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

*For patients of group 1:

• Patients with systemic sclerosis (ACR-EULAR Criteria)
• Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
• Patients consenting to participate to the study
• Patients enrolled in the national healthcare insurance program

For patients of group 2:

• Patients with other connective tissue disease (ACR specific-disease criteria)
• Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
• Patients consenting to participate to the study
• Patients enrolled in the national healthcare insurance program

For patients of group 3 (healthy volunteers)

• Patients eligible for blood donation (blood donation regulation criteria of January 11th 2022 decree)
• Patients without medical history of autoimmune systemic or chronic inflammatory systemic disease,
• Patients without current or past neoplasy disease,
• Patients without chronic metabolic pathology
• Patients without treatment by anti inflammatory or corticotherapy for the last 15 days,
• Patients without infectious pathology or inflammatory acute for the last 15 days
• Patients consenting to participate to the study

Exclusion Criteria

• Patients/Healthy volunteers under 18 years old
• Patients/Healthy volunteers protected by the law
• Patients/Healthy volunteers not consenting to participate to the study after information
• Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion
• Pregnant or breastfeeding women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CHU de Reims

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Chu Reims

Reims, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Kevin DIDIER, Dr.

Role: CONTACT

kdidier@chu-reims.fr

03.26.83.24.44

Facility Contacts

Damien JOLLY, Pr.

Role: primary

djolly@chu-reims.fr

326788472 ext. 33

References

Didier K, Giusti D, Le Jan S, Terryn C, Muller C, Pham BN, Le Naour R, Antonicelli FD, Servettaz A. Neutrophil Extracellular Traps Generation Relates with Early Stage and Vascular Complications in Systemic Sclerosis. J Clin Med. 2020 Jul 7;9(7):2136. doi: 10.3390/jcm9072136.

Reference Type: BACKGROUND

PMID: 32645862 (View on PubMed)

Other Identifiers

PO23126

Identifier Type: -

Identifier Source: org_study_id